A multinational research team led by Professor Małgorzata Kujawska at the Poznań University of Medical Sciences in Poland has found that graphene quantum dots (GQDs) — nanoscale carbon particles — can counteract the clumping of the protein α-synuclein (ASN), a hallmark of neurodegenerative diseases such as Parkinson's and multiple system atrophy (MSA). The study, published in the journal Science and Technology of Advanced Materials, details how GQDs interact with ASN to prevent the formation of toxic fibers that characterize these conditions.
The buildup of ASN into toxic clumps is associated with cellular dysfunction and progressive neuronal loss. Current treatments only manage symptoms rather than stopping the underlying protein clumping, prompting scientists to explore new strategies, including nanomaterials that can prevent these aggregates from forming or help clear them from the brain.
The study used a multi-stage approach, testing GQDs in cell-free environments, neuronal cultures, and animal models of MSA. When administered intranasally in mice, the particles significantly reduced the presence of toxic protein aggregates. Furthermore, the treatment appeared to activate autophagy, a biological recycling process that helps cells break down and remove damaged proteins.
At concentrations relevant to its biological effects, the GQDs showed a favorable safety profile, although some changes in cellular stress and immune responses were observed at higher doses. This is an important consideration, as many nanomaterials face hurdles in medical applications due to concerns over long-term biocompatibility.
“This study points to a promising new direction for strategies against neurodegenerative diseases,” says Professor Kujawska. “While clinical use of GQDs remains a long way off, these findings strengthen the case for further research.”
Challenges remain, such as preventing quantum dots from clumping in liquid suspensions. “GQDs may serve as a useful research tool,” says Professor Kujawska. “What we learn as we optimize their properties and conduct a comprehensive safety evaluation could help design more effective nanomaterial-based strategies not just for synucleinopathies, but also for other conditions characterized by the buildup of toxic proteins.”
